The hereditary testing market size has grown strongly in recent years. It will grow from $6.62 billion in 2025 to $7.23 billion in 2026 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to advancements in genetic sequencing technologies, increasing awareness of inherited disorders, expansion of clinical genetics programs, declining cost of genetic testing, growth of diagnostic laboratory networks.
The hereditary testing market size is expected to see strong growth in the next few years. It will grow to $10.17 billion in 2030 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to increasing integration of genomics into routine care, rising demand for precision medicine applications, expansion of population-scale genetic screening, growing use of digital genetic data platforms, increasing focus on preventive healthcare genomics. Major trends in the forecast period include increasing adoption of next-generation sequencing tests, rising demand for predictive and carrier genetic testing, growing use of AI-based variant interpretation, expansion of prenatal and newborn screening programs, enhanced focus on personalized genetic counseling.
The growing prevalence of genetic disorders is expected to drive the expansion of the hereditary testing market going forward. Genetic disorders are medical conditions caused by abnormalities or mutations in an individual’s deoxyribonucleic acid that are inherited from one or both parents or occur spontaneously. The increase in genetic disorders is partly attributed to rising parental age, which elevates the risk of genetic mutations being transmitted to offspring. Hereditary testing supports individuals with genetic disorders by enabling early detection, guiding personalized treatment approaches, and informing family planning decisions through the identification of inherited mutations. For example, in October 2024, according to the Cystic Fibrosis Trust, a UK-based charitable organization, the number of patients registered with cystic fibrosis increased to 11,318 in 2023 from 11,148 in 2022. Therefore, the rising prevalence of genetic disorders is fueling the growth of the hereditary testing market.
Major companies operating in the hereditary testing market are concentrating on technological advancements in genetic test kits to improve testing accuracy, shorten turnaround times, and enhance the detection of a wider range of genetic mutations. Genetic test kits are diagnostic tools designed to analyze an individual’s deoxyribonucleic acid (DNA) to identify genetic mutations or variations associated with inherited conditions or disease risk. For instance, in July 2023, Devyser Diagnostics AB, a Sweden-based biotechnology company specializing in the development, manufacturing, and commercialization of DNA diagnostic kits for hereditary disease testing, introduced two new targeted next-generation sequencing kits, Devyser LynchFAP and Devyser BRCA PALB2. Devyser LynchFAP enables comprehensive analysis of PMS2 by overcoming challenges associated with its pseudogene PMS2CL, along with nine other key genes linked to hereditary colorectal cancer syndromes. Devyser BRCA PALB2 offers a single-tube solution that screens BRCA1, BRCA2, and PALB2 mutations in both blood and tumor samples, designed to streamline laboratory workflows while providing efficient, user-friendly sequencing and dedicated software for confident detection of hereditary cancer risks.
In May 2025, GeneDx LLC, a US-based biotechnology company specializing in genetic testing, acquired Fabric Genomics for an undisclosed amount. Through this acquisition, GeneDx aims to strengthen its genomic interpretation capabilities by leveraging Fabric Genomics’ AI-powered platform, enhancing its hereditary disease diagnostic offerings and enabling faster, more scalable genetic analysis. Fabric Genomics is a US-based computational genomics company that provides hereditary testing solutions.
Major companies operating in the hereditary testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., CooperSurgical Inc., QIAGEN N.V, Natera Inc., Myriad Genetics Inc., Fulgent Genetics Inc, Invitae Corporation, GeneDx LLC, Twist Bioscience Corporation, Color Health Inc., MedGenome Inc, SOPHiA GENETICS SA, Gene By Gene Ltd., Dante Labs Inc., 23mofang Co. Ltd.
North America was the largest region in the hereditary testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hereditary testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the hereditary testing market by increasing costs of imported sequencing instruments, reagents, laboratory consumables, and bioinformatics hardware. Diagnostic laboratories and research institutes in North America and Europe are most affected due to reliance on imported genomic technologies, while Asia-Pacific faces higher costs for expanding testing infrastructure. These tariffs are raising testing prices and limiting access in cost-sensitive markets. However, they are also encouraging domestic manufacturing of testing kits, regional reagent production, and localized genomic research capabilities.
The hereditary testing market research report is one of a series of new reports that provides hereditary testing market statistics, including hereditary testing industry global market size, regional shares, competitors with a hereditary testing market share, detailed hereditary testing market segments, market trends and opportunities, and any further data you may need to thrive in the hereditary testing industry. This hereditary testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Hereditary testing, also known as genetic testing for inherited conditions, is a medical test that examines an individual’s deoxyribonucleic acid (DNA) to identify genetic mutations or variations inherited from parents. These tests are used to evaluate the risk of developing or transmitting inherited disorders, diagnose genetic diseases, and support personalized treatment or preventive care decisions.
The primary types of hereditary testing include predictive testing, carrier testing, prenatal testing, newborn screening, diagnostic testing, and others. Predictive testing involves the use of genetic or medical tests to determine the likelihood of an individual developing a particular disease or condition in the future before symptoms occur. Sample types include blood, saliva, tissue, buccal swabs, and urine, and the technologies used include next-generation sequencing (NGS), polymerase chain reaction (PCR), Sanger sequencing, microarray technology, and whole genome sequencing (WGS). These tests are applied across areas such as oncology, cardiovascular diseases, neurological disorders, metabolic disorders, and others, and are used by end users including hospitals, diagnostic laboratories, research institutes, pharmaceutical companies, patients, and consumers.
The hereditary testing market includes revenues earned by entities through services such as genetic screening, pharmacogenetic testing, and presymptomatic testing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The hereditary testing market size is expected to see strong growth in the next few years. It will grow to $10.17 billion in 2030 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to increasing integration of genomics into routine care, rising demand for precision medicine applications, expansion of population-scale genetic screening, growing use of digital genetic data platforms, increasing focus on preventive healthcare genomics. Major trends in the forecast period include increasing adoption of next-generation sequencing tests, rising demand for predictive and carrier genetic testing, growing use of AI-based variant interpretation, expansion of prenatal and newborn screening programs, enhanced focus on personalized genetic counseling.
The growing prevalence of genetic disorders is expected to drive the expansion of the hereditary testing market going forward. Genetic disorders are medical conditions caused by abnormalities or mutations in an individual’s deoxyribonucleic acid that are inherited from one or both parents or occur spontaneously. The increase in genetic disorders is partly attributed to rising parental age, which elevates the risk of genetic mutations being transmitted to offspring. Hereditary testing supports individuals with genetic disorders by enabling early detection, guiding personalized treatment approaches, and informing family planning decisions through the identification of inherited mutations. For example, in October 2024, according to the Cystic Fibrosis Trust, a UK-based charitable organization, the number of patients registered with cystic fibrosis increased to 11,318 in 2023 from 11,148 in 2022. Therefore, the rising prevalence of genetic disorders is fueling the growth of the hereditary testing market.
Major companies operating in the hereditary testing market are concentrating on technological advancements in genetic test kits to improve testing accuracy, shorten turnaround times, and enhance the detection of a wider range of genetic mutations. Genetic test kits are diagnostic tools designed to analyze an individual’s deoxyribonucleic acid (DNA) to identify genetic mutations or variations associated with inherited conditions or disease risk. For instance, in July 2023, Devyser Diagnostics AB, a Sweden-based biotechnology company specializing in the development, manufacturing, and commercialization of DNA diagnostic kits for hereditary disease testing, introduced two new targeted next-generation sequencing kits, Devyser LynchFAP and Devyser BRCA PALB2. Devyser LynchFAP enables comprehensive analysis of PMS2 by overcoming challenges associated with its pseudogene PMS2CL, along with nine other key genes linked to hereditary colorectal cancer syndromes. Devyser BRCA PALB2 offers a single-tube solution that screens BRCA1, BRCA2, and PALB2 mutations in both blood and tumor samples, designed to streamline laboratory workflows while providing efficient, user-friendly sequencing and dedicated software for confident detection of hereditary cancer risks.
In May 2025, GeneDx LLC, a US-based biotechnology company specializing in genetic testing, acquired Fabric Genomics for an undisclosed amount. Through this acquisition, GeneDx aims to strengthen its genomic interpretation capabilities by leveraging Fabric Genomics’ AI-powered platform, enhancing its hereditary disease diagnostic offerings and enabling faster, more scalable genetic analysis. Fabric Genomics is a US-based computational genomics company that provides hereditary testing solutions.
Major companies operating in the hereditary testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., CooperSurgical Inc., QIAGEN N.V, Natera Inc., Myriad Genetics Inc., Fulgent Genetics Inc, Invitae Corporation, GeneDx LLC, Twist Bioscience Corporation, Color Health Inc., MedGenome Inc, SOPHiA GENETICS SA, Gene By Gene Ltd., Dante Labs Inc., 23mofang Co. Ltd.
North America was the largest region in the hereditary testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hereditary testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the hereditary testing market by increasing costs of imported sequencing instruments, reagents, laboratory consumables, and bioinformatics hardware. Diagnostic laboratories and research institutes in North America and Europe are most affected due to reliance on imported genomic technologies, while Asia-Pacific faces higher costs for expanding testing infrastructure. These tariffs are raising testing prices and limiting access in cost-sensitive markets. However, they are also encouraging domestic manufacturing of testing kits, regional reagent production, and localized genomic research capabilities.
The hereditary testing market research report is one of a series of new reports that provides hereditary testing market statistics, including hereditary testing industry global market size, regional shares, competitors with a hereditary testing market share, detailed hereditary testing market segments, market trends and opportunities, and any further data you may need to thrive in the hereditary testing industry. This hereditary testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Hereditary testing, also known as genetic testing for inherited conditions, is a medical test that examines an individual’s deoxyribonucleic acid (DNA) to identify genetic mutations or variations inherited from parents. These tests are used to evaluate the risk of developing or transmitting inherited disorders, diagnose genetic diseases, and support personalized treatment or preventive care decisions.
The primary types of hereditary testing include predictive testing, carrier testing, prenatal testing, newborn screening, diagnostic testing, and others. Predictive testing involves the use of genetic or medical tests to determine the likelihood of an individual developing a particular disease or condition in the future before symptoms occur. Sample types include blood, saliva, tissue, buccal swabs, and urine, and the technologies used include next-generation sequencing (NGS), polymerase chain reaction (PCR), Sanger sequencing, microarray technology, and whole genome sequencing (WGS). These tests are applied across areas such as oncology, cardiovascular diseases, neurological disorders, metabolic disorders, and others, and are used by end users including hospitals, diagnostic laboratories, research institutes, pharmaceutical companies, patients, and consumers.
The hereditary testing market includes revenues earned by entities through services such as genetic screening, pharmacogenetic testing, and presymptomatic testing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Hereditary Testing Market Characteristics
3. Hereditary Testing Market Supply Chain Analysis
4. Global Hereditary Testing Market Trends and Strategies
5. Hereditary Testing Market Analysis of End Use Industries
7. Global Hereditary Testing Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Hereditary Testing Total Addressable Market (TAM) Analysis for the Market
9. Hereditary Testing Market Segmentation
10. Hereditary Testing Market Regional and Country Analysis
11. Asia-Pacific Hereditary Testing Market
12. China Hereditary Testing Market
13. India Hereditary Testing Market
14. Japan Hereditary Testing Market
15. Australia Hereditary Testing Market
16. Indonesia Hereditary Testing Market
17. South Korea Hereditary Testing Market
18. Taiwan Hereditary Testing Market
19. South East Asia Hereditary Testing Market
20. Western Europe Hereditary Testing Market
21. UK Hereditary Testing Market
22. Germany Hereditary Testing Market
23. France Hereditary Testing Market
24. Italy Hereditary Testing Market
25. Spain Hereditary Testing Market
26. Eastern Europe Hereditary Testing Market
27. Russia Hereditary Testing Market
28. North America Hereditary Testing Market
29. USA Hereditary Testing Market
30. Canada Hereditary Testing Market
31. South America Hereditary Testing Market
32. Brazil Hereditary Testing Market
33. Middle East Hereditary Testing Market
34. Africa Hereditary Testing Market
36. Hereditary Testing Market Competitive Landscape and Company Profiles
37. Hereditary Testing Market Other Major and Innovative Companies
40. Hereditary Testing Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Hereditary Testing Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses hereditary testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for hereditary testing? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hereditary testing market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Test Type: Predictive Testing; Carrier Testing; Prenatal Testing; Newborn Screening; Diagnostic Testing; Other Test Types2) By Sample Type: Blood Samples; Saliva Samples; Tissue Samples; Buccal Swabs; Amniotic Fluid And Cord Blood Samples
3) By Technology Used: Next-Generation Sequencing (NGS); Polymerase Chain Reaction (PCR); Sanger Sequencing; Microarray Technology; Whole Genome Sequencing (WGS)
4) By Application: Oncology; Cardiovascular Diseases; Neurological Disorders; Metabolic Disorders; Other Applications
5) By End User: Hospitals; Diagnostic Laboratories; Research Institutes; Pharmaceutical Companies; Patients And Consumers
Subsegments:
1) By Predictive Testing: Breast Cancer 1 (BRCA1) and Breast Cancer 2 (BRCA2) Gene Mutation Testing; Lynch Syndrome Testing; Familial Hypercholesterolemia Testing; Huntington’s Disease Testing; Cardiomyopathy Genetic Testing2) By Carrier Testing: Cystic Fibrosis Carrier Screening; Tay-Sachs Carrier Screening; Spinal Muscular Atrophy (SMA) Carrier Screening; Thalassemia Carrier Screening; Sickle Cell Carrier Testing
3) By Prenatal Testing: Non-Invasive Prenatal Testing (NIPT); Chorionic Villus Sampling (CVS); Amniocentesis; Expanded Carrier Screening (Prenatal Context); Cell-Free Fetal Deoxyribonucleic Acid Testing
4) By Newborn Screening: Phenylketonuria (PKU) Screening; Congenital Hypothyroidism Screening; Cystic Fibrosis Screening; Sickle Cell Disease Screening; Hearing Loss and Metabolic Disorder Panels
5) By Diagnostic Testing: Rare Disease Genetic Testing; Inherited Cancer Diagnostic Testing; Cardiogenetic Diagnostic Panels; Neurogenetic Disorder Testing; Monogenic Disease Panels
6) By Other Test Types: Pharmacogenomics Testing; Preimplantation Genetic Diagnosis (PGD); Whole Exome Sequencing (WES); Whole Genome Sequencing (WGS); Mitochondrial Deoxyribonucleic Acid Testing
Companies Mentioned: F. Hoffmann-La Roche Ltd.; Thermo Fisher Scientific Inc.; Laboratory Corporation of America Holdings; Quest Diagnostics Incorporated; Agilent Technologies Inc.; Illumina Inc.; CooperSurgical Inc.; QIAGEN N.V; Natera Inc.; Myriad Genetics Inc.; Fulgent Genetics Inc; Invitae Corporation; GeneDx LLC; Twist Bioscience Corporation; Color Health Inc.; MedGenome Inc; SOPHiA GENETICS SA; Gene By Gene Ltd.; Dante Labs Inc.; 23mofang Co. Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Hereditary Testing market report include:- F. Hoffmann-La Roche Ltd.
- Thermo Fisher Scientific Inc.
- Laboratory Corporation of America Holdings
- Quest Diagnostics Incorporated
- Agilent Technologies Inc.
- Illumina Inc.
- CooperSurgical Inc.
- QIAGEN N.V
- Natera Inc.
- Myriad Genetics Inc.
- Fulgent Genetics Inc
- Invitae Corporation
- GeneDx LLC
- Twist Bioscience Corporation
- Color Health Inc.
- MedGenome Inc
- SOPHiA GENETICS SA
- Gene By Gene Ltd.
- Dante Labs Inc.
- 23mofang Co. Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 7.23 Billion |
| Forecasted Market Value ( USD | $ 10.17 Billion |
| Compound Annual Growth Rate | 8.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
